Free Trial

→ 2 Pro Traders… 4 Livestreams… 4 Live Trades (From Monument Traders Alliance) (Ad)

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 14 of 20

Slide 14

Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. Read More

Current Stock Price: $73.09
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $108.60 (48.6% Upside)

Slide 14

2 Pro Traders… 4 Livestreams… 4 Live Trades (Ad)

The Zero Day Loophole: The Secret of HUGE Overnight Profits from Government Reports

Get 4 Trades for $4

More From MarketBeat

web analytics

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

Sign In
Create Account

Your Email Address:

Your Password:

Log In

or

Sign in with Google

Forgot your password?

Your Email Address:

Choose a Password:

or

Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.